Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. reported that senior vice president and chief human resources officer Andrea L. Frohning acquired additional equity-linked awards on January 9, 2026. She received 392.387 shares of common stock at a price of $0, described as dividends on restricted stock units that are credited as additional RSUs and vest on the same schedule as the underlying awards. After this, she beneficially owned 34,002.252 shares of common stock directly.
Frohning also acquired 22.7283 shares of phantom stock at $12.22 per unit under a Supplemental Executive Retirement Plan, bringing her total phantom stock holdings to 1,759.2738 units. Each phantom stock unit and each RSU is economically equivalent to one share of common stock, with phantom stock payable in common stock upon her termination of employment and RSUs converting into common stock on a 1:1 basis at vesting.
DENTSPLY SIRONA Inc. reported that senior vice president and chief human resources officer Andrea L. Frohning acquired additional equity-linked awards on January 9, 2026. She received 392.387 shares of common stock at a price of $0, described as dividends on restricted stock units that are credited as additional RSUs and vest on the same schedule as the underlying awards. After this, she beneficially owned 34,002.252 shares of common stock directly.
Frohning also acquired 22.7283 shares of phantom stock at $12.22 per unit under a Supplemental Executive Retirement Plan, bringing her total phantom stock holdings to 1,759.2738 units. Each phantom stock unit and each RSU is economically equivalent to one share of common stock, with phantom stock payable in common stock upon her termination of employment and RSUs converting into common stock on a 1:1 basis at vesting.
DENTSPLY SIRONA Inc. director Willie A. Deese reported an automatic stock-related transaction. On 01/09/2026, he acquired 201.508 shares of common stock at a price of $0. These shares represent dividends on previously granted restricted stock units (RSUs), paid in the form of additional RSUs that carry the same vesting schedule as the original awards.
Following this transaction, Deese directly beneficially owned 57,748.066 shares of DENTSPLY SIRONA common stock. Each RSU converts into one share of common stock on a 1:1 basis, and the dividend RSUs vest at the same time as the underlying RSUs they relate to.
DENTSPLY SIRONA Inc. director Willie A. Deese reported an automatic stock-related transaction. On 01/09/2026, he acquired 201.508 shares of common stock at a price of $0. These shares represent dividends on previously granted restricted stock units (RSUs), paid in the form of additional RSUs that carry the same vesting schedule as the original awards.
Following this transaction, Deese directly beneficially owned 57,748.066 shares of DENTSPLY SIRONA common stock. Each RSU converts into one share of common stock on a 1:1 basis, and the dividend RSUs vest at the same time as the underlying RSUs they relate to.
DENTSPLY SIRONA Inc. VP and Chief Accounting Officer Kevin Czerney reported routine equity-related awards. On January 9, 2026, he acquired 262.7169 shares of common stock at $0, representing dividends paid in the form of additional restricted stock units that follow the same vesting schedule as the underlying RSUs, each converting into one share of common stock.
On the same date, he also acquired 4.0523 shares of phantom stock under the Dentsply Supplemental Savings Plan and 45.13 shares of phantom stock under the Supplemental Executive Retirement Plan at an economic value of $12.22 per phantom share, each economically equivalent to one share of common stock and payable in stock upon termination of employment. Following these transactions, his reported holdings increased to 28,040.786 shares of common stock, 341.201 phantom shares in the savings plan, and 3,493.4336 phantom shares in the retirement plan.
DENTSPLY SIRONA Inc. VP and Chief Accounting Officer Kevin Czerney reported routine equity-related awards. On January 9, 2026, he acquired 262.7169 shares of common stock at $0, representing dividends paid in the form of additional restricted stock units that follow the same vesting schedule as the underlying RSUs, each converting into one share of common stock.
On the same date, he also acquired 4.0523 shares of phantom stock under the Dentsply Supplemental Savings Plan and 45.13 shares of phantom stock under the Supplemental Executive Retirement Plan at an economic value of $12.22 per phantom share, each economically equivalent to one share of common stock and payable in stock upon termination of employment. Following these transactions, his reported holdings increased to 28,040.786 shares of common stock, 341.201 phantom shares in the savings plan, and 3,493.4336 phantom shares in the retirement plan.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an automatic stock-related transaction. On 01/09/2026, he acquired 245.816 shares of common stock at a price of $0, bringing his directly held beneficial ownership to 17,944.987 shares.
The new shares come from dividends on restricted stock units (RSUs). These dividends were credited in the form of additional RSUs that follow the same vesting schedule as the original RSU awards. Each RSU converts into one share of common stock when it vests, so the reported amount reflects stock tied to his existing equity compensation rather than an open-market purchase.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an automatic stock-related transaction. On 01/09/2026, he acquired 245.816 shares of common stock at a price of $0, bringing his directly held beneficial ownership to 17,944.987 shares.
The new shares come from dividends on restricted stock units (RSUs). These dividends were credited in the form of additional RSUs that follow the same vesting schedule as the original RSU awards. Each RSU converts into one share of common stock when it vests, so the reported amount reflects stock tied to his existing equity compensation rather than an open-market purchase.
DENTSPLY SIRONA Inc. reported that its Board of Directors, following a recommendation from the Corporate Governance and Nominating Committee, increased the size of the Board from 10 to 11 members, effective January 10, 2026.
On the same date, the Board appointed Donald J. Zurbay as a director, with his term running until the election of directors at the 2026 annual meeting of stockholders. He will also serve on the Board’s Audit and Finance Committee. The company notes that he has no family relationships with existing leaders and no material related-party transactions requiring disclosure. He will receive the same compensation as other non-employee directors. The company furnished, but did not file, a press release about his appointment as Exhibit 99.1.
DENTSPLY SIRONA Inc. reported that its Board of Directors, following a recommendation from the Corporate Governance and Nominating Committee, increased the size of the Board from 10 to 11 members, effective January 10, 2026.
On the same date, the Board appointed Donald J. Zurbay as a director, with his term running until the election of directors at the 2026 annual meeting of stockholders. He will also serve on the Board’s Audit and Finance Committee. The company notes that he has no family relationships with existing leaders and no material related-party transactions requiring disclosure. He will receive the same compensation as other non-employee directors. The company furnished, but did not file, a press release about his appointment as Exhibit 99.1.
DENTSPLY SIRONA Inc. director reports open-market stock purchase
A director of DENTSPLY SIRONA Inc. (XRAY) reported buying common stock in the company. On 11/24/2025, the reporting person purchased 9,337 shares of common stock at a price of $10.71 per share, in an open-market transaction coded as a purchase. After this transaction, the director beneficially owns 57,342.925 shares of DENTSPLY SIRONA common stock, held directly. This filing is a routine Form 4 disclosure of insider trading activity required under U.S. securities regulations.
DENTSPLY SIRONA Inc. reported a leadership update, appointing Michael Pomeroy as interim Chief Financial Officer effective November 25, 2025. He will serve in this temporary role while the company searches for a permanent Chief Financial Officer.
During this period, President and Chief Executive Officer Daniel T. Scavilla will continue to act as the company’s principal financial officer in addition to his role as principal executive officer. Pomeroy brings extensive finance leadership experience across industrial, healthcare, consumer, and distribution businesses, including prior CFO roles at Icahn Automotive Group, Hollander-Keeco, and RGIS, and a recent interim CFO role at spinal devices company Highridge Medical.
DENTSPLY SIRONA (XRAY) disclosed a Form 4 for an officer, SVP and Chief Supply Chain Office, reporting two stock option grants on 11/07/2025. The filings show awards of 417,200 options at an exercise price of $11.18 and 361,700 options at $12.3, each recorded as an acquisition (Code A) with $0 option price, indicating grants. Both grants are held directly and will cliff-vest on the third anniversary of the grant date (11/07/2028), with expiration on 11/07/2035. The second grant’s exercise price equals 110% of the issuer’s closing price on the grant date.
DENTSPLY SIRONA filed an 8-K/A to disclose separation terms for former CFO Matthew E. Garth. The Separation Agreement provides separation payments totaling $1,200,000, paid in two installments of $600,000 each, plus $32,430 for twelve months of COBRA coverage and twelve months of outplacement services.
Mr. Garth remains eligible to earn a prorated portion (5/36ths) of his May 30, 2025 performance restricted share units based on actual achievement at the end of the performance period. All other unvested equity is forfeited and canceled. Payments and benefits are contingent on his execution and nonrevocation of a release of claims and compliance with post-termination restrictive covenants.
Dentsply Sirona (XRAY) reported Q3 2025 results with net sales of $904 million versus $951 million a year ago and an operating loss of $218 million. The quarter included $262 million of goodwill and intangible asset impairments, leading to a net loss of $427 million, or $2.14 per share.
Sales declined in the United States to $291 million from $374 million, while Europe rose to $382 million from $347 million. Segment mix showed Essential Dental Solutions at $357 million and Orthodontic and Implant Solutions at $205 million; Wellspect Healthcare increased to $83 million from $72 million.
Year to date, net sales were $2.719 billion versus $2.888 billion, with $497 million of impairments and a net loss of $452 million. Cash from operating activities was $134 million year to date, ending cash was $363 million. Long‑term debt was $2,017 million and current debt was $378 million. Goodwill decreased to $1,270 million from $1,597 million, and total equity was $1,478 million.